US20090186803A1 - Use of nutritional compositions with phospholipid, sphingolipid and cholesterol. - Google Patents

Use of nutritional compositions with phospholipid, sphingolipid and cholesterol. Download PDF

Info

Publication number
US20090186803A1
US20090186803A1 US12/158,931 US15893106A US2009186803A1 US 20090186803 A1 US20090186803 A1 US 20090186803A1 US 15893106 A US15893106 A US 15893106A US 2009186803 A1 US2009186803 A1 US 2009186803A1
Authority
US
United States
Prior art keywords
oligosaccharides
composition
lipid
total
infant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/158,931
Other languages
English (en)
Inventor
Renate Maria Louise Zwijsen
Günther Boehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutricia NV
Original Assignee
Nutricia NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37964343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20090186803(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP20050077972 external-priority patent/EP1800675B1/en
Priority claimed from PCT/NL2006/050274 external-priority patent/WO2008054192A1/en
Application filed by Nutricia NV filed Critical Nutricia NV
Assigned to N.V. NUTRICIA reassignment N.V. NUTRICIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BOEHM, GUNTHER, ZWIJSEN, RENATE MARIA LOUISE
Publication of US20090186803A1 publication Critical patent/US20090186803A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to preventing obesity by administering a nutritional composition to non-obese infants with the age below 3 years.
  • the present invention relates to the treatment and/or prevention of type 2 diabetes.
  • breast-feeding is the preferred method of feeding infants. However, there are circumstances that make breast-feeding impossible or less desirable. In those cases infant formulae are a good alternative.
  • the composition of modem infant formulae is adapted in such a way that it meets many of the special nutritional requirements of the fast growing and developing infant.
  • EP 1566439 pertains to a method for preventing and/or treating obesity.
  • WO 2005/051091 relates to a substantially homogenous lipid preparation comprising a combination of glycerophospholipids being phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS) and phosphatidylinositol (PI), wherein the quantitative ratio between said glycerophospholipids essentially mimics their corresponding ratio in naturally occurring human milk fat (HMF), optionally further comprising sphingomyelin (SM) and/or cholesterol, wherein the quantitative ratio between the glycerophospholipids in said combination and the sphingomyelin and/or cholesterol essentially mimics their corresponding ratio in said naturally occurring HMF.
  • JP05292880 relates to buttermilk fat for inhibiting lipase activity.
  • the present invention provides a composition wherein the lipid fraction is enriched in polar lipids, more particularly in glycerophospholipids, sphingolipids (especially sphingomyelin) and cholesterol. It was surprisingly found by the inventors that administration of a composition comprising glycerophospholipids, sphingolipids (especially sphingomyelin) and cholesterol decreases insulin secretion when added to a nutritional composition, compared to the insulin secretion induced by the same nutritional formula without the present polar lipids.
  • the present invention can therefore advantageously be used to prevent obesity later-in-life, but also to prevent the development of diabetes later in life.
  • Inclusion of the present combination in infant nutrition reduces blood insulin levels and thereby the prevents the development of obesity and/or diabetes later in life. Since in infants high blood insulin levels particularly stimulate visceral adipocyte proliferation, the composition is particularly suitable to prevent visceral obesity.
  • the present invention can also suitably be used for the manufacture of a nutritional composition for the prevention of type 2 diabetes, and/or for the dietary management of type 2 diabetes.
  • the present invention provides the use of a composition comprising a lipid, protein and digestible carbohydrate component and (a) 0.5 to 20 wt. % phospholipids based on total lipid; (b) 0.1 to 20 wt. % sphingolipids based on total lipid; and (c) 0.005 to 10 wt. % cholesterol based on total lipid, for the manufacture of a nutritional composition to be administered to a (non-obese) infant with the age below 36 months for the prevention of obesity and/or type 2 diabetes.
  • the present invention provides the use of a composition comprising a lipid, protein and digestible carbohydrate component and (a) 0.5 to 20 wt. % phospholipids based on total lipid; (b) 0.1 to 20 wt. % sphingolipids based on total lipid; and (c) 0.005 to 10 wt.
  • % cholesterol based on total lipid for the manufacture of a nutritional composition to be administered to an infant with the age below 36 months for preventing the development of a disorder when said human has an age above 36 months, wherein said disorder is selected from the group consisting of type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea.
  • the present invention provides the use of a composition comprising a lipid, protein and digestible carbohydrate component and: (a) 0.5 to 20 wt. % phospholipids based on total lipid; (b) 0.1 to 20 wt. % sphingolipids based on total lipid; and (c) 0.005 to 10 wt. % cholesterol based on total lipid, for the manufacture of a nutritional composition for the prevention of type 2 diabetes and/or for the dietary management of type 2 diabetes.
  • the present composition is preferably administered to a non-obese human infant with the age below 36 months, preferably below 18 months, more preferably below 12 months, even more preferably below 6 months.
  • the present composition is administered to a non-overweight human with the age below 36 months, preferably below 18 months, more preferably below 12 months, even more preferably below 6 months of age.
  • the absence or presence of obesity and/or overweight in an infant can suitably be determined by a physician.
  • a non-obese infant below 36 months of age has gender specific weight-for-length below the 95 th percentile, more preferably below the 85 th percentile. Gender specific weight-for-length percentiles have been published by Center for Disease Control and Prevention (CDC) in 2000.
  • central obesity refers to a condition with increased visceral fat mass.
  • a waist circumference above 102 cm in adult man or above 88 cm in adult women indicates central obesity.
  • For children of 3-19 years old appropriate cut-offs for age- and sex-dependent waist circumferences can be found in Taylor et al, 2000 Am J Clin Nutr 72:490-495.
  • the present composition comprises a lipid component.
  • the present composition comprises phospholipids, sphingolipids and cholesterol. Additionally the present composition preferably comprises triglycerides.
  • the lipid component provides preferably 35 to 55% of the total calories. More preferably the present composition comprises a lipid component providing 40 to 50% of the total calories.
  • the composition When in liquid form, e.g. as a ready-to-feed liquid, the composition preferably comprises 2.1 to 6.5 g lipid per 100 ml, more preferably 3.0 to 4.0 g per 100 ml. Based on dry weight the present composition preferably comprises 12.5 to 40 wt. % lipid, more preferably 19 to 30 wt. %.
  • oral administration of a composition comprising phospholipids, sphingolipids and cholesterol has the advantage that it decreases the post-prandial insulin response (see example 1), particularly when co-administered with a nutritional composition.
  • the present composition comprises phospholipids.
  • phospholipids as used in the present invention particularly refers to glycerophospholipids.
  • Glycerophospholipids are normally a class of lipids formed from fatty acids esterified at the hydroxyl groups on carbon-1 and carbon-2 of the backbone glycerol moiety and a negatively-charged phosphate group attached to carbon-3 of the glycerol via an ester bond, and optionally a choline group (in case of phosphatidylcholine), a serine group (in case of phosphatidylserine), an ethanolamine group (in case of phosphatidylethanolamine), an inositol group (in case of phosphatidylinositol) or a glycerol group (in case of phosphatidylglycerol) attached to the phosphate group.
  • a choline group in case of phosphatidylcholine
  • serine group in case of
  • the present composition contains phosphatidylcholine (PC), phosphatidylserine, phosphatidylinositol and/or phosphatidylethanolamine, more preferably at least phosphatidylcholine.
  • PC phosphatidylcholine
  • phosphatidylserine phosphatidylserine
  • phosphatidylinositol phosphatidylethanolamine
  • the present composition comprises sphingolipids.
  • sphingolipids as in the present invention particularly refers to glycolipids with an amino alcohol sphingosine.
  • the sphingosine backbone is O-linked to a (usually) charged headgroup such as ethanolamine, serine or choline backbone.
  • the backbone is also amide linked to a fatty acyl group.
  • Sphingolipids include sphingomyelin, ceramides, and glycosphingolipids.
  • the present composition contains sphingomyelin and/or glycosphingolipids.
  • Glycosphingolipids are ceramides with one or more sugar residues joined in a ⁇ -glycosidic linkage at the 1-hydroxyl position.
  • Glycosphingolipids may be further subdivided into cerebrosides, globosides and gangliosides.
  • Cerebrosides have a single glucose or galactose at the 1-hydroxy position, while gangliosides have at least three sugars, one of which must be sialic acid.
  • Sphingomyelins have a phosphorylcholine or phosphoroethanolamine molecule esterified to the 1-hydroxy group of a ceramide.
  • the present composition contains gangliosides.
  • the composition comprises sphingolipids, more preferably sphingomyelin and/or gangliosides, more preferably at least one ganglioside selected from the group consisting of GM3 and GD3.
  • the present composition comprises cholesterol.
  • the cholesterol is believed to further contribute to a reduced occurrence of obesity and/or type 2 diabetes.
  • a further beneficial effect of dietary cholesterol is that it inhibits the endogenous cholesterol synthesis during infancy and programmes the endogenous cholesterol synthesis to lower levels. Consequently, reduced blood cholesterol levels later in life will be achieved. This results in a drop of LDL-cholesterol value in blood and a raise of HDL cholesterol value in blood during adolescence and adulthood.
  • the present composition comprises 0.5 to 20 wt. % phospholipids based on total lipid, more preferably 1 to 10 wt. %, even more preferably 4 to 8 wt. %.
  • the present composition comprises 0.1 to 20 wt. % sphingolipids based on total lipid, more preferably 0.5 to 10 wt. %, even more preferably 2 to 8 wt%.
  • the present composition comprises 0.5 to 20 wt. % (sphingolipids plus phospholipids) based on total lipid, more preferably 1 to 10 wt. %, even more preferably 4 to 8 wt%.
  • the present composition preferably comprises at least 0.005 wt.
  • % cholesterol based on total fat more preferably at least 0.01 wt. %, more preferably at least 0.05 wt. %., even more preferably at least 0.1 wt. %.
  • the amount of cholesterol does not exceed 10 wt. % based on total lipid, more preferably does not exceed 5 wt. %, even more preferably does not exceed 1 wt. % of total lipid.
  • the amount of cholesterol is 0.5 to 0.7 wt. % based on total lipid.
  • Preferred sources for providing the phospholipids, sphingolipids and cholesterol are egg lipids, milk fat, buttermilk fat and butter serum fat.
  • a preferred source for phospholipids, particularly PC, is soy lecithin.
  • the present composition preferably comprises soy lecithin, egg lipid, milk fat, butter serum fat and/or buttermilk fat, more preferably buttermilk fat.
  • the present composition preferably comprises 0.05 to 10 grams buttermilk fat per 100 gram dry weight of the composition, preferably 0.1 to 3 gram. These amounts of buttermilk fat provide the blood insulin reducing effects.
  • the buttermilk fat and butter serum fat is typically obtained from the manufacture of buttermilk and in particular from the whey that remains after manufacturing cheese from buttermilk.
  • This milk whey comprises a relatively high amount of small fat globules, especially when macromolecules such as ⁇ -lactoglobulin have been removed.
  • the concentration of small fat globules can be increased by applying filtration techniques on skimmed products, which concentrate the lipid layer on one side of the membrane and remove molecules like salts and lactose.
  • Fractions that are enriched with acidic sphingoglycolipids can also be isolated by applying chromatographic methods known in the art such as ion exchange.
  • the buttermilk or butter serum fat contains at least 4 wt. % phospholipids per 100 gram lipid, more preferably 7 to 75 wt. %, most preferably 30 to 70 wt. % phospholipids per 100 gram lipid.
  • the composition comprises digestible carbohydrate.
  • the digestible carbohydrate component preferably provides 30 to 60% of the total calories.
  • Preferably the present composition comprises a digestible carbohydrate component provides 40 to 50% of the total calories.
  • Preferred digestible carbohydrate sources are lactose, glucose, sucrose, fructose, galactose, maltose, starch and maltodextrin.
  • the maintenance of insulin sensitivity, while reducing blood insulin levels can improved by inclusion of a low glycaemic carbohydrate in the present composition, preferably lactose.
  • the present composition preferably comprises lactose.
  • the present composition preferably comprises a digestible carbohydrate component, wherein at least 35 wt. %, more preferably at least 50 wt. %, more preferably at least 75 wt. %, even more preferably at least 90 wt. %, most preferably at least 95 wt. % is lactose.
  • the present composition preferably comprises at least 25 grams lactose per 100 gram dry weight of the present composition, preferably at least 40 grams lactose/100 gram.
  • a high blood insulin levels stimulate glucose uptake in adipose tissue, resulting in an increased adipose tissue mass.
  • the high insulin levels contribute to increased proliferation of adipocytes, at least partly due to the increased glucose uptake, and thereby in an increased chance of obesity later in life.
  • the present composition therefore preferably maintains low insulin levels. It was found that non-digestible oligosaccharides (NDO) that can be fermented (particularly galacto-oligosaccharides) have a blood insulin tempering effect, and consequently contribute to a reduced change on obesity later-in-life (see example 2). Furthermore, the combination of phospholipids, sphingolipids, cholesterol and non-digestible oligosaccharide is particularly effective in reducing blood insulin levels. It was surprisingly found that the combination of phospholipids, sphingolipids, cholesterol reduced the postprandial insulin secretion of non-digestible oligosaccharide containing nutritional compositions.
  • lactose as the (main) digestible carbohydrate source.
  • lactose as the (main) digestible carbohydrate source.
  • the present composition comprises non-digestible oligosaccharides with a DP between 2 and 60.
  • the composition preferably prevents the onset of insulin resistance.
  • the non-digestible oligosaccharide is preferably selected from the group consisting of fructo-oligosaccharides (including inulin), galacto-oligosaccharides (including transgalacto-oligosaccharides), gluco-oligosaccharides (including gentio-, nigero- and cyclodextrin-oligosaccharides), arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides.
  • the present composition comprises fructo-oligosaccharides, galacto-oligosaccharides and/or galacturonic acid oligosaccharides, more preferably galacto-oligosaccharides, most preferably transgalacto-oligosaccharides.
  • the composition comprises a mixture of transgalacto-oligosaccharides and fructo-oligosaccharides.
  • the present composition comprises galacto-oligosaccharides with a DP of 2-10 and/or fructo-oligosaccharides with a DP of 2-60.
  • the galacto-oligosaccharide is preferably selected from the group consisting of transgalacto-oligosaccharides, lacto-N-tetraose (LNT), lacto-N-neotetraose (neo-LNT), fucosyl-lactose, fucosylated LNT and fucosylated neo-LNT.
  • the present method comprises the administration of transgalacto-oligosaccharides ([galactose] n -glucose; wherein n is an integer between 1 and 60, i.e. 2, 3, 4, 5, 6, . . . , 59, 60; preferably n is selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10).
  • Transgalacto-oligosaccharides are for example sold under the trademark VivinalTM (Borculo Domo Ingredients, Netherlands).
  • the saccharides of the transgalacto-oligosaccharides are ⁇ -linked.
  • Fructo-oligosaccharide is a NDO comprising a chain of ⁇ linked fructose units with a DP or average DP of 2 to 250, more preferably 10 to 100.
  • Fructo-oligosaccharide includes inulin, levan and/or a mixed type of polyfructan. An especially preferred fructo-oligosaccharide is inulin.
  • Fructo-oligosaccharide suitable for use in the compositions is also already commercially available, e.g.
  • Uronic acid oligosaccharides are preferably obtained from pectin degradation.
  • the present composition preferably comprises a pectin degradation product with a DP between 2 and 100.
  • the pectin degradation product is prepared from apple pectin, beet pectin and/or citrus pectin.
  • the composition comprises transgalacto-oligosaccharide, fructo-oligosaccharide and a pectin degradation product.
  • the weight ratio transgalacto-oligosaccharide:fructo-oligosaccharide:pectin degradation product is preferably 20 to2:1:1 to 3, more preferably 12 to 7:1:1 to 2.
  • LA refers to linoleic acid (18:2 n6)
  • ALA refers to ⁇ -linolenic acid (18:3 n3)
  • LC-PUFA refers to long chain polyunsaturated fatty acids and/or acyl chains comprising at least 20 carbon atoms in the fatty acyl chain and with 2 or more unsaturated bonds
  • DHA refers to docosahexaenoic acid (22:6, n3)
  • EPA refers to eicosapentaenoic acid (20:5 n3)
  • ARA refers to arachidonic acid (20:4 n6)
  • DPA refers to docosapentaenoic acid (22:5 n3)
  • DHGLA refers to dihomogammalinolenic acid (20:3 n6).
  • Medium chain fatty acids (MCFA) refer to fatty acids and/or acyl chains with a chain length of 6, 8 or 10 carbon atoms. MCFA may also be
  • LA preferably is present in a sufficient amount in order to promote a healthy growth and development, yet in an amount as low as possible to prevent occurrence of obesity later in life.
  • the composition therefore preferably comprises less than 15 wt. % LA based on total fatty acids, preferably between 5 and 14.5 wt. %, more preferably between 6 and 12 wt. %.
  • ALA should be present in a sufficient amount to promote a healthy growth and development of the infant.
  • the present composition therefore preferably comprises at least 1.0 wt. % based on total fatty acids.
  • the composition comprises at least 1.6 wt. % ALA based on total fatty acids, more preferably at least 2.0 wt. %.
  • the composition comprises less than 10 wt. % ALA, more preferably 5.0 wt. % based on total fatty acids.
  • the weight ratio LA/ALA should be well balanced in order to prevent obesity, especially central obesity, while at the same time ensuring a normal growth and development. Therefore, the present composition preferably comprises a weight ratio of LA/ALA between 2 and 15, more preferably between 2 and 7, more preferably between 3 and 6, even more preferably between 4 and 5.5, even more preferably between 4 and 5.
  • the present composition preferably comprises at least 3 wt. % MCFA based on total fatty acids, more preferably at least 10 wt. %, even more preferably 15 wt. %. Since MCFA reduces body fat deposition with no preference for central fat mass, the present composition advantageously comprises less than 50 wt. % MCFA based on total fatty acids, more preferably less than 40 wt. %, even more preferably less than 25 wt. %.
  • the present composition comprises LC-PUFA, since LC-PUFA reduce obesity later in life, more preferably central obesity. More preferably, the present composition comprises n-3 LC-PUFA, even more preferably EPA, DPA and/or DHA, even more preferably DHA. It was found that these n-3 LC-PUFA decrease obesity.
  • the content of n-3 LC-PUFA in the present composition preferably does not exceed 15 wt. % of the total fatty acid content, preferably does not exceed 10 wt. %, even more preferably does not exceed 5 wt. %.
  • the present composition comprises at least 0.2 wt. %, preferably at least 0.5 wt. %, more preferably at least 0.75 wt. %, n-3 LC-PUFA of the total fatty acid content.
  • the present composition comprises relatively low amounts of AA.
  • the n-6 LC-PUFA content preferably does not exceed 5 wt. %, more preferably does not exceed 0.8 wt. %, more preferably does not exceed 0.75 wt. %, even more preferably does not exceed 0.5 wt. %, based on total fatty acids. Since AA is important in infants for optimal functional membranes, especially membranes of neurological tissues, the amount of n-6 LC-PUFA is preferably at least 0.02 wt.
  • AA is advantageous in a composition low in LA since it remedies LA deficiency.
  • the presence of, preferably low amounts, of AA is beneficial in nutrition to be administered to infants below the age of 6 months, since for these infants the infant formulae is generally the only source of nutrition.
  • the weight ratio n-6 LC-PUFA/n-3 LC-PUFA in the present infant nutrition is preferably low in order to prevent obesity later in life.
  • the composition comprises a weight ratio of n-6 LC-PUFA/n-3 LC-PUFA below 1.5, more preferably below 1.0, even more preferably below 0.6.
  • the amount of saturated fatty acids is preferably below 58 wt. % based on total fatty acids, more preferably below 45 wt. %.
  • the concentration of monounsaturated fatty acids preferably ranges from 17 to 60% based on weight of total fatty acids
  • LA, ALA, MCFA and/or LC-PUFA are preferably provided as free fatty acids, in triglyceride form, in diglyceride form, in monoglyceride form, in phospholipid form, or as a mixture of one of more of the above.
  • the present composition contains LC-PUFA in triglyceride and/or phospholipid form, even more preferably phospholipid form since LC-PUFA in phospholipid form are better incorporated into membranes.
  • the present composition contains MCFA in triglyceride form.
  • the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil (flaxseed oil), rape seed oil (including colza oil, low erucic acid rape seed oil and canola oil), salvia oil, perilla oil, purslane oil, lingonberry oil, sea buckthorn oil, hemp oil, high oleic sunflower oil, high oleic safflower oil, olive oil, fish oil (especially tuna oil), single cell oil (including algal, microbial oil and fungal oil), black currant seed oil, echium oil, butter fat, coconut oil and palm kernel oil.
  • the present composition comprises at least one, preferably at least two lipid sources selected from the group consisting of linseed oil, rapeseed oil, coconut oil, high oleic sunflower oil, butter oil, single cell oil and fish oil.
  • n-3 LC-PUFA single cell oil including algal oil and microbial oil
  • these oil sources have a low EPA/DHA ratio, which results in an increased anti-obesity effect.
  • More preferably fish oil (even more preferably tuna oil) is used as a source of n-3 LC-PUFA since they have a higher EPA concentration which is advantageous since EPA is precursor of eicosanoids which have an additional anti-obesity effect.
  • the present composition preferably comprises a source of uridine and/or choline.
  • the composition comprises a source of uridine and choline.
  • Choline is preferably added as choline chloride.
  • the present composition preferably comprises choline chloride.
  • the present composition preferably comprises at least 0.035 wt. % choline based on dry weight of the composition, more preferably at least 0.045 wt. %.
  • the present composition comprises no more than 1 wt. % choline based on total dry weight of the present composition, more preferably below 0.5 wt. %, even more preferably below 0.1 wt. %.
  • the presence of choline has the advantage that it is an excellent methyldonor.
  • the composition of the present invention preferably comprises choline.
  • the choline resulting from phospholipids is not calculated to contribute to this amount of methyl donor.
  • the present composition comprises uridine in the form of a nucleotide, nucleoside and/or base.
  • the present composition comprises uridine 5′-monophospate and/or salts thereof (collectively abbreviated to UMP), in particular monosodium salts thereof.
  • the composition comprises 0.001 to 0.1 wt. % UMP based on dry weight of the present composition, more preferably 0.002 to 0.05 wt. %, most preferably 0.002 to 0.025 wt. %.
  • UMP is preferably be added to the composition in a mixture of nucleotides.
  • the present composition comprises proteins.
  • the protein component preferably provides 5 to 15% of the total calories.
  • Preferably the present composition comprises a protein component provides 6 to 12% of the total calories.
  • the composition comprises vegetable protein and/or animal (non-human) milk protein.
  • the composition comprises hydrolyzed casein and/or hydrolyzed whey protein. It was found that administration of a composition wherein the protein comprises hydrolyzed casein and/or hydrolyzed whey results in reduced post-prandial levels of both insulin and glucose compared to the administration of a composition comprising intact casein and intact whey protein.
  • the present composition more preferably comprises more preferably casein hydrolysate and whey protein hydrolysate because the amino acid composition of bovine casein is more similar to the amino acid composition found in human milk protein and whey protein is easier to digest and found in greater ratios in human milk.
  • the present composition is particularly suitable for providing the daily nutritional requirements to an infant with the age below 36 months, particularly an infant with the age below 24 months, even more preferably an infant with the age below 18 months, most preferably below 12 months of age.
  • the present composition comprises a lipid, protein and digestible carbohydrate component wherein the lipid component preferably provides 35 to 55% of the total calories, the protein component preferably provides 5 to 15% of the total calories and the digestible carbohydrate component preferably provides 30 to 60% of the total calories.
  • the present composition comprises a lipid component providing 40 to 50% of the total calories, a protein component provides 6 to 12% of the total calories and a digestible carbohydrate component provides 40 to 50% of the total calories.
  • the present composition is not human breast milk.
  • the present composition preferably comprises (i) vegetable lipid and/or animal (non-human) fat; and/or (ii) vegetable protein and/or animal (non-human) milk protein.
  • the present composition preferably does not comprise a proteinase inhibitor, preferably not a trypsin inhibitor, chymotrypsin inhibitor or elastase inhibitor.
  • the present composition is not human milk.
  • the compositions of the inventions preferably comprise other fractions, such as vitamins, minerals according to international directives for infant formulae.
  • Adipocytes including visceral adipocytes, proliferate during the first 36 months of life as well as (more limited) in puberty.
  • the amount of adipocytes is an important determinant in the degree of obesity later-in-life.
  • the present composition is preferably administered to the infant during the first 3 years of life. It was found that there is a predominance of proliferation of (visceral) adipocytes in the first 12 months of life (with an optimum in perinatal adipocyte proliferation). Hence, it is particularly preferred that the present composition is administered to the infant in this period of life.
  • the present composition is therefore advantageously administered to a human of 0-24 months, more preferably to a human of 0-18 months, most preferably to a human of 0-12 months.
  • the present invention particularly aims to prevent obesity later-in-life and is preferably not an obesity treatment.
  • the present composition is preferably administered to an infant not suffering from obesity or childhood obesity, particularly a non-obese infant more preferably an infant that does not suffer from overweight.
  • the present composition is preferably administered orally to the infant.
  • the present invention also aims to prevent the occurrence of obesity and or diabetes at the age above 36 months, particularly to prevent obesity at the age above 8 years, particularly above 15 years, more particularly above 18 years.
  • the composition is used to prevent obesity, more preferably central obesity, since especially central obesity is related to health disorders such as type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea, more preferably type 2 diabetes.
  • health disorders such as type 2 diabetes, fasting hyperglycaemia, insulin resistance, visceral adiposity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidaemia, hyperuricaemia, fatty liver, osteoarthritis and sleep apnoea, more preferably type 2 diabetes.
  • Nutritional compositions A complete infant formula comprising lactose, galacto-oligosacharides with a DP 2-6 and fructo-oligosaccharides with DP 7-60 with extra added phospholipids (0.2 g/100 ml) was manufactured using a commercially available buttermilk/butter serum concentrate of Lactalis as source. An infant formula with a comparable composition, but without added phospholipids was used as control. The concentration of phospholipids was about 6.3 wt. % based on total lipid in the experimental formula and about 0.75 wt. % based on total lipid in the control formula.
  • the experimental composition comprised about 1.4 wt. % sphingomyelin based on total lipid and about 4 wt. % cholesterol based on total lipid. The amount of sphingomyelin and cholesterol was negligible in the control formula.
  • Infant nutrition comprising a lipid component providing 48% of the total calories, a protein component providing 8% of the total calories and a digestible carbohydrate component providing 44% of the total calories;

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pediatric Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
US12/158,931 2005-12-23 2006-12-22 Use of nutritional compositions with phospholipid, sphingolipid and cholesterol. Abandoned US20090186803A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05077972.7 2005-12-23
EP20050077972 EP1800675B1 (en) 2005-12-23 2005-12-23 Composition comprising polyunsaturated fatty acids, proteins, manganese and/or molybden and nucleosides/nucleotides for treating dementia
NLPCT/NL2006/050274 2006-11-02
PCT/NL2006/050274 WO2008054192A1 (en) 2006-11-02 2006-11-02 Use of nutritional compositions for preventing disorders
PCT/NL2006/050331 WO2007073194A2 (en) 2005-12-23 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2006/050331 A-371-Of-International WO2007073194A2 (en) 2005-12-22 2006-12-22 Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/057,324 Continuation US20160175393A1 (en) 2005-12-23 2016-03-01 Use of nutritional compositions with phospholipid sphingolipid and cholesterol

Publications (1)

Publication Number Publication Date
US20090186803A1 true US20090186803A1 (en) 2009-07-23

Family

ID=37964343

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/158,931 Abandoned US20090186803A1 (en) 2005-12-23 2006-12-22 Use of nutritional compositions with phospholipid, sphingolipid and cholesterol.
US12/158,857 Abandoned US20110136732A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
US13/357,109 Active 2027-05-16 US8871218B2 (en) 2005-12-23 2012-01-24 Infant nutritional compositions for preventing obesity
US15/057,324 Abandoned US20160175393A1 (en) 2005-12-23 2016-03-01 Use of nutritional compositions with phospholipid sphingolipid and cholesterol

Family Applications After (3)

Application Number Title Priority Date Filing Date
US12/158,857 Abandoned US20110136732A1 (en) 2005-12-23 2006-12-22 Infant nutritional compositions for preventing obesity
US13/357,109 Active 2027-05-16 US8871218B2 (en) 2005-12-23 2012-01-24 Infant nutritional compositions for preventing obesity
US15/057,324 Abandoned US20160175393A1 (en) 2005-12-23 2016-03-01 Use of nutritional compositions with phospholipid sphingolipid and cholesterol

Country Status (14)

Country Link
US (4) US20090186803A1 (enExample)
EP (4) EP1962617A2 (enExample)
JP (1) JP2009521214A (enExample)
CN (1) CN103054048B (enExample)
AU (3) AU2006327995B2 (enExample)
BR (3) BRPI0620466A2 (enExample)
CA (3) CA2634693A1 (enExample)
ES (1) ES2537080T3 (enExample)
HU (1) HUE026440T2 (enExample)
MY (2) MY149164A (enExample)
PL (1) PL1962823T3 (enExample)
PT (1) PT1962823E (enExample)
RU (3) RU2444210C2 (enExample)
WO (3) WO2007073192A2 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195128A1 (en) * 2008-10-09 2011-08-11 Kay Patricia Palmano Treating or preventing gout
US20130071446A1 (en) * 2010-03-17 2013-03-21 Eline Marleen Van Der Beek Infant nutrition for improving fatty acid composition of brain membranes
EP2836084B1 (en) 2012-04-10 2016-12-21 Hero AG A nutritional composition
CN114554873A (zh) * 2019-10-29 2022-05-27 Aak股份有限公司 包含乳磷脂和蛋磷脂的营养组合物
US11376222B2 (en) 2013-11-01 2022-07-05 N.V. Nutricia Lipid composition for improving body composition during catch-up growth
US11389403B2 (en) 2015-10-15 2022-07-19 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
US11632974B2 (en) 2016-12-09 2023-04-25 N.V. Nutricia Nutritional composition for improving cell membranes

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
CA2697942A1 (en) * 2007-09-07 2009-03-12 Nestec S.A. Range of shelf stable infant foods which include only "naturally contained" sugars and methods for making the same
PT2190304E (pt) 2007-09-17 2012-03-20 Nutricia Nv Formulação nutricional com alto teor energético
CN101909467B (zh) 2007-11-01 2013-04-24 恩兹默泰克有限公司 用于婴儿营养的脂质混合物
RU2478309C2 (ru) * 2007-12-21 2013-04-10 Н.В. Нютрисиа Применение сфингомиелина и неперевариваемых углеводов для нормализации микробиоты кишечника
US20100310725A1 (en) * 2007-12-31 2010-12-09 Kathleen Reidy Nutritionally appropriate menu of food products for children
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
EP2296494B2 (en) * 2008-06-16 2022-05-18 N.V. Nutricia Infant milk formula with fat gradient
US9491955B2 (en) 2008-08-25 2016-11-15 Brandeis University Balanced myristate- and laurate-containing edible oil
SI2554056T1 (sl) * 2008-09-02 2020-02-28 N.V. Nutricia Prehranski sestavki z lipidnimi globulami velikega premera z oblogo, ki obsega fosfolipide
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
MX2011004921A (es) * 2008-12-08 2011-05-30 Nestec Sa Modulacion de la grasa corporal infantil.
WO2010068086A1 (en) * 2008-12-11 2010-06-17 N.V. Nutricia Nutritional compositions with large lipid globule size
WO2010081604A1 (en) * 2009-01-19 2010-07-22 Nestec S.A. Nutritional composition for infants
WO2010106384A1 (fr) * 2009-03-16 2010-09-23 Societe La Biochimie Appliquee (Solabia) Compositions nutraceutiques, pharmaceutiques ou alimentaires a base de gluco-oligosaccharides
AU2010230362B2 (en) * 2009-04-01 2015-01-15 Société des Produits Nestlé S.A. Reduction of risk of obesity
WO2010119088A2 (en) * 2009-04-15 2010-10-21 Bodo Melnik Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity
WO2011071367A1 (en) 2009-12-11 2011-06-16 N.V. Nutricia Metabolic imprinting effects of structured lipids
PL2353595T3 (pl) 2010-01-19 2016-03-31 Mjn Us Holdings Llc Kompensacja żywieniowa w diecie typu zachodniego
JP5581071B2 (ja) 2010-02-03 2014-08-27 花王株式会社 ミトコンドリア機能向上剤
EP2452572A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
JP2014506891A (ja) * 2011-02-16 2014-03-20 ピヴォタル セラピューティクス インコーポレイテッド 心血管疾患（ＣＶＤ）患者の食事管理のためのω３脂肪酸診断アッセイ
EP2675442A1 (en) * 2011-02-16 2013-12-25 Pivotal Therapeutics, Inc. Cholesterol absorption inhibitor (azetidinone) and omega 3 fatty acids (epa, dha, dpa) for the reduction of cholesterol and for the reduction of cardiovascular events
WO2012112520A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. A formulations comprising omega 3 fatty acids and an anti obesity agent for the reduction of body weight in cardiovascular disease patients (cvd) and diabetics
CA2827579A1 (en) * 2011-02-16 2012-08-23 Pivotal Therapeutics, Inc. Omega 3 formulations comprising epa, dha and dpa for treatment of risk factors for cardiovascular disease
EP2514435A1 (en) * 2011-04-19 2012-10-24 Nestec S.A. Infant formula for use in the prevention of cardiovascular diseases
WO2012173467A1 (en) 2011-06-16 2012-12-20 N.V. Nutricia Metabolic imprinting effects of specifically designed lipid component
WO2013036102A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with cholesterol
WO2013036103A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with large lipid globules
CN103889240B (zh) * 2011-10-18 2016-09-14 雀巢产品技术援助有限公司 用于增加胰岛素敏感性和/或降低胰岛素抵抗性的组合物
EP2583562A1 (en) 2011-10-21 2013-04-24 Nestec S.A. Use of whey protein micelles for infants at risk of obesity or diabetes
EP3384902B1 (en) * 2012-02-17 2020-12-30 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
WO2013191533A1 (en) * 2012-06-18 2013-12-27 N.V. Nutricia Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
WO2014058301A1 (en) * 2012-10-12 2014-04-17 N.V. Nutricia Infant nutrition with lipid globules to increase energy expenditure and metabolic flexibility later in life
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
EP2991508A1 (en) * 2013-04-10 2016-03-09 Nestec S.A. Infant formula with a low content of mcfas in specific proportions and a relatively high content of unsaturated fatty acids, and its use in promoting the healthy establishment of cognitive function in infants
RU2648375C2 (ru) * 2013-04-10 2018-03-26 Нестек С.А. Детская смесь с низким содержанием жирных кислот со средней длиной цепи в определенных пропорциях и ее применение при стимуляции и/или обеспечении сбалансированного роста грудных детей
SE537951C2 (sv) * 2013-07-01 2015-12-01 Hero Ag Profylaktisk användning av modersmjölksersättning mot otit
CN105744845A (zh) * 2013-11-29 2016-07-06 雀巢产品技术援助有限公司 具有磷脂的营养组合物
CN105765587A (zh) * 2013-11-29 2016-07-13 雀巢产品技术援助有限公司 评估婴儿或者幼儿在以后生活中的肥胖症风险的设备、系统和方法
EP3073844B1 (en) * 2013-11-29 2020-01-22 Société des Produits Nestlé S.A. Age-tailored nutritional compositions with a varying protein content
EP3079497B1 (en) 2013-12-12 2019-10-23 Société des Produits Nestlé S.A. Synthetic milk compositions comprising n-6 eicosatrienoic acid and polar lipids for infants younger and older than three months for healthy establishment of cognitive function
MX384125B (es) * 2013-12-12 2025-03-14 Soc Des Produits Nestle S A Star Composiciones sintéticas de leche para infantes menores que tres meses de edad y para infantes y niños mayores que tres meses para asegurar el crecimiento óptimo y prevenir la obesidad.
RU2689550C1 (ru) * 2013-12-12 2019-05-28 Нестек С.А. Искусственные молочные композиции, содержащие полиненасыщенные жирные кислоты (ПНЖК), для содействия здоровому развитию когнитивной функции у младенцев и детей младшего возраста мужского и женского пола
WO2015086170A1 (en) 2013-12-12 2015-06-18 Nestec S.A. Synthetic milk compositions for optimal growth and development and prevention of obesity in male and female infant and children
JP6336750B2 (ja) * 2013-12-19 2018-06-06 雪印メグミルク株式会社 脂肪蓄積抑制剤
WO2016050754A1 (en) * 2014-09-30 2016-04-07 Nestec S.A. Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses.
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10835544B2 (en) 2014-12-08 2020-11-17 Glycom A/S Synthetic composition for regulating satiety
US10987368B2 (en) 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
EP3285602A1 (en) * 2015-04-21 2018-02-28 Enzymotec Ltd. Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation
JP6613661B2 (ja) * 2015-07-08 2019-12-04 花王株式会社 食品に対する内臓脂肪のつきにくさの評価方法
WO2017129645A1 (en) * 2016-01-26 2017-08-03 Nestec S.A. COMPOSITIONS COMPRISING 2FL AND LNnT TO CONTROL FOOD INTAKE AND GROWTH IN INFANTS OR YOUNG CHILDREN
MX382374B (es) * 2016-04-11 2025-03-13 Soc Des Produits Nestle S A Star Nutrición infantil que proporciona beneficios metabólicos.
WO2017183956A1 (en) * 2016-04-18 2017-10-26 N.V. Nutricia Linoleic acid and alpha-linolenic acid for use for reducing early-life stress induced cognitive decline
BR112018071493A2 (pt) * 2016-04-18 2019-02-19 N.V. Nutricia usos de ácido linoleico (la) e ácido alfa-linolênico (ala) na fabricação de uma composição nutricional, composição nutricional, método para prevenir declínio no funcionamento cognitivo induzido e método para prevenir redução na neurogênese induzida por estresse precoce
EP3471562A4 (en) * 2016-06-15 2020-07-29 Glycom A/S Synthetic compositions comprising human milk oligosaccharides for use the prevention and treatment of disorders
EP3645024B1 (en) 2017-06-30 2022-09-14 N.V. Nutricia Synbiotic composition for preventing fatty liver disease
EP3645023B1 (en) 2017-06-30 2022-09-14 N.V. Nutricia Synbiotic composition for preventing hyperinsulinemia and insulin resistance
JP2021514608A (ja) * 2018-02-23 2021-06-17 フイルメニツヒ ソシエテ アノニムＦｉｒｍｅｎｉｃｈ Ｓａ 貯蔵安定性のある粉末組成物
US12005083B1 (en) 2019-06-24 2024-06-11 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
US11849747B1 (en) 2019-06-24 2023-12-26 PBM Nutritionals, LLC Nutritional compositions with MFGM and certain human milk oligosaccharides and uses thereof
CN114052243A (zh) * 2020-07-29 2022-02-18 江苏伯克投资管理有限公司 山羊乳提取物的制备及其在全营养特殊医学用途配方食品中的应用
CN112972488B (zh) * 2021-03-02 2022-12-23 青岛农业大学 一种具有抗高尿酸血症活性的岩藻寡糖及其制备方法和应用
CN118102890A (zh) * 2021-10-13 2024-05-28 雀巢产品有限公司 用于改善睡眠的营养组合物
WO2023208925A1 (en) 2022-04-25 2023-11-02 N.V. Nutricia Nutritional composition for use in preventing programmed obesity in female infants

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782019A (en) * 1983-04-11 1988-11-01 Meito Sangyo Kabushiki Kaisha Enzymatic production of sphingophospholipid derivatives
EP0484266A2 (en) * 1990-10-30 1992-05-06 Puleva Union Industrial Y Agro-Ganadera, S.A. Fat mixture for infant and adult nutrition
US20020035733A1 (en) * 1999-11-05 2002-03-21 Luthman L Holger Congenic animal models of non-insulin dependent diabetes mellitus
US20040071824A1 (en) * 2000-12-27 2004-04-15 Van Laere Katrien Maria Jozefa Nutritional composition with health promoting action contaning oligosaccharides
US20050175759A1 (en) * 2004-02-09 2005-08-11 Atul Singhal Newborn infant formulas and feeding methods

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366914A (en) * 1992-01-29 1994-11-22 Nec Corporation Vertical power MOSFET structure having reduced cell area
US5602109A (en) * 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US6194009B1 (en) * 1996-11-22 2001-02-27 Princeton Nutrition, Llc Refrigeration-shelf-stable ultra-pasteurized or pasteurized infant formula
ID22744A (id) * 1997-02-21 1999-12-09 Abbott Lab Cs Metoda dan komposisi untuk mengurangi pengaruh dari nekrotisasi enterkolitis
JPH10262607A (ja) * 1997-03-28 1998-10-06 Snow Brand Milk Prod Co Ltd 乳幼児用栄養組成物
US6413557B1 (en) * 1997-07-02 2002-07-02 Kyung Ja Lee Soy-containing nutrition supplement and process
ATE230935T1 (de) * 1997-07-22 2003-02-15 Nestle Sa Lipidzusammensetzung für säuglingsnährpräparat und herstellungsverfahren
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US6579551B1 (en) * 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
ATE228779T1 (de) * 1999-01-20 2002-12-15 Nutricia Nv Säuglingsnährpräparat
PL199861B1 (pl) * 1999-04-29 2008-11-28 Nestle Sa Preparat dla niemowląt i sposób wytwarzania preparatu
JP3544493B2 (ja) * 1999-06-10 2004-07-21 雪印乳業株式会社 乳幼児用栄養組成物
US7090862B2 (en) * 2001-03-30 2006-08-15 Abbott Laboratories Method of improving the antioxidant status of an infant
WO2003005836A2 (en) * 2001-07-10 2003-01-23 Trustees Of Boston University Modified-fat nutritional products useful for preventing or treating obesity
IL150240A (en) * 2002-06-16 2005-07-25 Lipogen Ltd Infant formula supplemented with phospholipids
AU2003251557A1 (en) * 2002-06-28 2004-01-19 Richard C. Theuer Fat compositions for infant formula and methods therefor
SE526943C2 (sv) * 2002-08-26 2005-11-22 Indevex Ab Födoämneskompositionsprodukt
US6753350B1 (en) * 2003-03-24 2004-06-22 Bristol-Myers Squibb Company Method to reduce the incidence of intraventricular hemorrhage in preterm infants
US6998392B2 (en) * 2003-04-02 2006-02-14 Mti Meta Tech Inc. Formulation to treat or prevent parasitic infection
RU2346448C2 (ru) * 2003-06-23 2009-02-20 Нестек С.А. Смесь для детей первых месяцев жизни или старше
EP1643862A1 (en) * 2003-06-24 2006-04-12 University of Kansas Medical Center Infant formula
IL158554A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
WO2005063050A1 (en) 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
EP1566439A1 (en) 2004-02-20 2005-08-24 Nestec S.A. Preventing or treating obesity
EP2705849B1 (en) * 2004-07-19 2018-04-04 N.V. Nutricia A preparation for use of aspartate for regulating glucose levels in blood
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
US20080274945A1 (en) * 2004-11-26 2008-11-06 N.V. Nutricia Infant Nutrition With Protease Inhibitor
CN101087539A (zh) * 2004-12-27 2007-12-12 雀巢技术公司 蛋白质含量降低的婴儿配方的用途
DK1855550T3 (da) * 2005-02-28 2012-01-16 Nutricia Nv Næringspræparat med probiotika
KR101355850B1 (ko) * 2005-03-08 2014-01-27 네스텍 소시에테아노님 식품용 압출 고형 제품
US20070191264A1 (en) * 2005-05-05 2007-08-16 Bristol-Myers Squibb Company, A Delaware Corporation Methods for inhibiting the growth of bacteria

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782019A (en) * 1983-04-11 1988-11-01 Meito Sangyo Kabushiki Kaisha Enzymatic production of sphingophospholipid derivatives
EP0484266A2 (en) * 1990-10-30 1992-05-06 Puleva Union Industrial Y Agro-Ganadera, S.A. Fat mixture for infant and adult nutrition
US20020035733A1 (en) * 1999-11-05 2002-03-21 Luthman L Holger Congenic animal models of non-insulin dependent diabetes mellitus
US20040071824A1 (en) * 2000-12-27 2004-04-15 Van Laere Katrien Maria Jozefa Nutritional composition with health promoting action contaning oligosaccharides
US20050175759A1 (en) * 2004-02-09 2005-08-11 Atul Singhal Newborn infant formulas and feeding methods

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
Backhed F, H Ding, T Wang, LV Hooper, GY Koh, A Nagy, CF Semenkovich, and JI Gordon. 2004. The gut microbiota as an environmental factor that regulates fat storage. PNAS; 101(44): 15718-15723. *
Bains. Drug Discovery World. pages 9-19. publication year: 2004. *
Boehm et al., Oligosaccharides from Milk, The Journal of Nutrition, pages 847S-849S; publication year: 2007. *
Bray and Popkin. Am J Clin Nutr Vol 68, pages 1157-1173; publication year: 1998. *
Cefalu. ILAR Journal. Vol 47, No. 3. pages 186-198. publication year: 2006 *
Chalk, MB. 2004. Obesity: Addressing a multifactorial disease. The Case Manager; 15(6): 47-49. *
Chandler et al. Drug Class Reviews. pages 1-46. publication year: 2005 *
Child-Specific Exposure Factors Handbook. Ch. 15 Human Milk Intake. pages 1-48, publication year: 2008 *
Darwish et al. Hunger Health and Society [online]. United Nations University Website, avaliable online from at least 2014. [retrieved on 04/18/2014]. Retrieved from the internet: . *
Edvardsson et al. J Lipid Research. Vol 40, pages 1177-1184. publication year: 1999. *
FDA website. Drugs Conducting Clinical Trials [online]. FDA, 2009 [retirieved on 08/19/2015]. Retrieved from the internet: . *
Grant and Meigs Current Diabetes Reviews Vol 2, pages 261-269. publication year: 2006. *
Hubert et al. Circulation, Vol 67, No 5, pages 968-977; publication year: 1983. *
Jenness R. The composition of human milk. Semin Perinatol. Vol 3, 1979 *
MedicalNewsToday. Direct Association Between Type 2 Diabetes And Obesity Found [online]. medicalnewstoday, 2013 [retrieved on 04/09/2014]. Retrieved from the internet: . *
Owen et al. Pediatrics Vol 115, No. 5 pages 1367-1377; publication date 5 May 2005. *
White et al. Clinical Diabetes. Vol 21, No. 1 pages 14-21. publication year: 2003. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110195128A1 (en) * 2008-10-09 2011-08-11 Kay Patricia Palmano Treating or preventing gout
US20130071446A1 (en) * 2010-03-17 2013-03-21 Eline Marleen Van Der Beek Infant nutrition for improving fatty acid composition of brain membranes
US9474764B2 (en) * 2010-03-17 2016-10-25 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes
US10548869B2 (en) 2010-03-17 2020-02-04 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes
EP2836084B1 (en) 2012-04-10 2016-12-21 Hero AG A nutritional composition
EP3175719B1 (en) 2012-04-10 2019-09-04 Hero AG A nutritional composition
US11647777B2 (en) 2012-04-10 2023-05-16 Semper Ab Nutritional composition
US11376222B2 (en) 2013-11-01 2022-07-05 N.V. Nutricia Lipid composition for improving body composition during catch-up growth
US11389403B2 (en) 2015-10-15 2022-07-19 N.V. Nutricia Infant formula with special lipid architecture for promoting healthy growth
US11632974B2 (en) 2016-12-09 2023-04-25 N.V. Nutricia Nutritional composition for improving cell membranes
CN114554873A (zh) * 2019-10-29 2022-05-27 Aak股份有限公司 包含乳磷脂和蛋磷脂的营养组合物

Also Published As

Publication number Publication date
AU2006327995A1 (en) 2007-06-28
AU2006327995B2 (en) 2012-09-13
US20160175393A1 (en) 2016-06-23
BRPI0620465A2 (pt) 2011-11-16
PL1962823T3 (pl) 2015-08-31
MY149164A (en) 2013-07-31
WO2007073192A3 (en) 2007-08-16
MY162091A (en) 2017-05-31
AU2006327996B2 (en) 2012-03-29
JP2009521214A (ja) 2009-06-04
EP2305049A1 (en) 2011-04-06
WO2007073194A3 (en) 2008-06-12
US20120121757A1 (en) 2012-05-17
EP1973424B1 (en) 2019-09-11
US20110136732A1 (en) 2011-06-09
CA2634117A1 (en) 2007-06-28
RU2008130365A (ru) 2010-01-27
RU2417712C2 (ru) 2011-05-10
WO2007073193A2 (en) 2007-06-28
RU2444210C2 (ru) 2012-03-10
US8871218B2 (en) 2014-10-28
CA2634895A1 (en) 2007-06-28
CN103054048A (zh) 2013-04-24
AU2006327996A1 (en) 2007-06-28
WO2007073193A3 (en) 2007-08-16
BRPI0620466A2 (pt) 2011-11-16
RU2008130370A (ru) 2010-01-27
ES2537080T3 (es) 2015-06-02
HUE026440T2 (en) 2016-06-28
CA2634693A1 (en) 2007-06-28
AU2006327997A8 (en) 2008-07-31
PT1962823E (pt) 2015-06-29
RU2008130367A (ru) 2010-01-27
CN103054048B (zh) 2014-11-19
WO2007073194A2 (en) 2007-06-28
EP1973424A2 (en) 2008-10-01
WO2007073192A2 (en) 2007-06-28
BRPI0620451A2 (pt) 2011-04-12
EP1962617A2 (en) 2008-09-03
EP1962823B1 (en) 2015-03-04
EP1962823A2 (en) 2008-09-03
AU2006327997A1 (en) 2007-06-28
AU2006327997B2 (en) 2012-03-29
RU2414905C2 (ru) 2011-03-27

Similar Documents

Publication Publication Date Title
EP1962823B1 (en) Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
USRE45483E1 (en) Infant nutritional compositions for preventing obesity
EP2861087B1 (en) Metabolic imprinting effects of nutrition with large lipid globules comprising milk fat and vegetable fat
EP2542101B1 (en) Modulation of post-prandial fat absorption
NZ569264A (en) Infant nutritional compositions for preventing obesity comprising linoleic acid
EP2753192A1 (en) Infant nutrition for regulating food intake later in life

Legal Events

Date Code Title Description
AS Assignment

Owner name: N.V. NUTRICIA, NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZWIJSEN, RENATE MARIA LOUISE;BOEHM, GUNTHER;REEL/FRAME:022502/0424

Effective date: 20080708

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION